Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:ZBIO News 22 December 2025 - 6 January 2026

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma shares dropped 5.8% to $15.66 in premarket trading Tuesday, extending a 52% plunge after Phase 3 data for obexelimab in IgG4-related disease. The drug met its main goal but fell short of results seen with Amgen’s Uplizna, prompting Morgan Stanley to downgrade the stock and cut its price target. Zenas plans to file for FDA approval in Q2 2026.
6 January 2026
··
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma shares were unchanged at $39.05 in premarket trading Tuesday after falling 8.1% Monday. The stock is down about 12% from its December 24 high as investors await Phase 3 INDIGO trial results expected around year-end. Monday’s session saw shares dip to $38.96 before closing at $39.05. Technical support is near $37.78, with resistance just above $41.
30 December 2025
·
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is having one of those classic biotech days where the market starts acting like it can see the future. On Monday, December 22, 2025, ZBIO surged roughly 14% and traded around $41.23 by early afternoon Eastern time—after touching a fresh all-time high near $41.67, according to multiple market data reports. MarketBeat+1 The timing isn’t subtle: Zenas is approaching a pivotal clinical-data moment for its lead asset obexelimab, and Wall Street research desks are increasingly framing the stock as a near-term catalyst setup—high potential reward, high potential whiplash. Below is a full roundup of the news,
22 December 2025
·

Stock Market Today

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

7 February 2026
Morgan Stanley shares rose 2.34% to $179.96 Friday, snapping a three-day slide as the Dow closed above 50,000 for the first time. About 9.1 million MS shares traded hands. The rebound followed Thursday’s 2.35% drop and came amid renewed rate-cut speculation and surging AI spending. Morgan Stanley remains 6.6% below its January high.
Lam Research stock price jumps 8% as chip rally returns — what to watch next week

Lam Research stock price jumps 8% as chip rally returns — what to watch next week

7 February 2026
Lam Research shares surged 8.3% to $231.01 Friday, with after-hours trading flat. The move followed a broad rally in chip stocks, pushing the PHLX semiconductor index up 5.7% as Nvidia, AMD, and Broadcom advanced. Lam announced a $0.26 quarterly dividend and a senior executive exercised 53,925 shares. Investors await U.S. jobs and inflation data next week.
Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

7 February 2026
Goldman Sachs shares jumped 4.3% to $928.75 Friday after confirming it is working with AI startup Anthropic on internal “AI agents.” The stock’s rally helped lift the Dow above 50,000 for the first time. Delayed U.S. jobs and inflation data are due midweek and could affect rate expectations. Goldman also filed for new structured notes tied to the Russell 2000 and S&P 500.
Go toTop